Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Phase 1
- Conditions
- Chronic Myeloid LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
- Interventions
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Fusion Pharma LLC
- Target Recruit Count
- 65
- Registration Number
- NCT02885766
- Locations
- 🇷🇺
Federal Haematological Scientific Center, Moscow, Russian Federation
🇷🇺Moscow City Centre of Hematology based on City Hospital named by S.Botkin, Moscow, Russian Federation
🇷🇺Federal Almazov North-West Medical Research Centre, St. Petersburg, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath